Back to School: How biopharma can reboot drug development. Access exclusive analysis here
One will compare time to disease progression with ISIS 2922 plus ganciclovir with ganciclovir alone.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury